LEXINGTON, Mass.,
June 21, 2017
/PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an
immuno-oncology company with a pipeline of immune checkpoint
antibodies and cancer vaccines, invites investors and the
general public to its Annual Meeting of Stockholders to begin at
5:00 p.m. ET on Wednesday, June 28, 2017. The meeting will be
held at the Company's headquarters located at 3 Forbes Road,
Lexington, MA 02421. Registration
for attendees starts at 4:30 p.m.
ET.
Webcast Information
A live webcast will be accessible from the Company's
website at http://investor.agenusbio.com/presentation-webcasts. The
archived replay will be available on the Agenus website for at
least 60 days following the meeting.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused
on the discovery and development of therapies that engage the
body's immune system to fight cancer. The Company's vision is to
expand the patient populations benefiting from cancer immunotherapy
by pursuing a number of combination approaches that leverage a
broad repertoire of antibody therapeutics and proprietary cancer
vaccine platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For
more information, please
visit www.agenusbio.com;
information that may be important to investors will be
routinely posted on our website.
Forward Looking Statements
This
press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities
laws, including statements regarding the Company's upcoming Annual
Meeting. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our most recent
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact:
Agenus
Inc.
Michelle Linn,
781-674-4541
michelle.linn@agenusbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/agenus-to-webcast-annual-meeting-of-stockholders-300477377.html
SOURCE Agenus Inc.